How to manage a severe form of euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors: a case report and literature review
Abstract
The use of sodium-glucose cotransporter-2 inhibitors is becoming increasingly widespread not only for the treatment of diabetes mellitus, but also for heart failure and kidney disease. However, these medications can lead to very severe complications, sometimes even fatal, such as Euglycemic Ketoacidosis (EDKA). In this report, we present the case of a 79-year-old woman, affected by type 2 diabetes mellitus on insulin therapy and empagliflozin, who was admitted to our emergency department for a severe EDKA. Treatment with bicarbonates did not improve her condition worsening the hypokalaemia and complicating the administration of insulin. For this reason, we decided to administer octreotide subcutaneously with a rapid resolution of EDKA and an improvement in clinical conditions, demonstrating that octreotide can be an excellent therapeutic option for EDKA. Starting from our experience, we conducted a review of the relevant literature on this issue.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.